BioCardia, Inc. [Nasdaq: BCDA] has announced the initiation of patient enrollment for its CardiAMP HF II pivotal study at Henry Ford Health in Detroit, Michigan. The study focuses on ischemic heart failure with reduced ejection fraction (HFrEF). This confirmatory trial is designed to evaluate an autologous bone marrow-derived mononuclear cell therapy aimed at promoting microvascular repair, reducing fibrosis, and increasing capillary density in patients with ischemic heart failure. The therapy involves harvesting cells from the patient on the day of the procedure, processing them at the bedside, and delivering them using minimally invasive catheter systems. The procedure concludes with the placement of high doses of the patient's own cells adjacent to damaged zones in the heart. Results from this ongoing trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.